Last updated on October 2018

Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Brief description of study

gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.

Clinical Study Identifier: NCT02560948

Contact Investigators or Research Sites near you

Start Over

Claus Bachert, Prof Dr

University Hospital Ghent
Ghent, Belgium

Enrico Iemoli, MD

Clinica dell'Azienda Opsedaliera Luigi Sacco
Milano, Italy

Joachin Sastre, Prof, Dr

Fundacion Jim nez Diaz
Madrid, Spain